Pasithea Therapeutics Corp

Company Profile

Pasithea Therapeutics Corp had its IPO on 2021-09-15 under the ticker symbol KTTA.

The company operates in the Healthcare sector and Biotechnology industry. Pasithea Therapeutics Corp has a staff strength of 15 employees.

Stock update

Shares of Pasithea Therapeutics Corp opened at $0.53 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.52 - $0.55, and closed at $0.54.

This is a +2.13% increase from the previous day's closing price.

A total volume of 8,387 shares were traded at the close of the day’s session.

In the last one week, shares of Pasithea Therapeutics Corp have slipped by -12.1%.

Pasithea Therapeutics Corp's Key Ratios

Pasithea Therapeutics Corp has a market cap of $15.95 million, indicating a price to book ratio of 0.6064 and a price to sales ratio of 93.068.

In the last 12-months Pasithea Therapeutics Corp’s revenue was $486559 with a gross profit of $-2213 and an EBITDA of $-16811744. The EBITDA ratio measures Pasithea Therapeutics Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Pasithea Therapeutics Corp’s operating margin was -3528.27% while its return on assets stood at -23.54% with a return of equity of -39.78%.

In Q2, Pasithea Therapeutics Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 1498.1%.

Pasithea Therapeutics Corp’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.67 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Pasithea Therapeutics Corp’s profitability.

Pasithea Therapeutics Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.3988. Its price to sales ratio in the trailing 12-months stood at 93.068.

Pasithea Therapeutics Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$38.15 million

Total Liabilities

$2.23 million

Operating Cash Flow

$0

Capital Expenditure

$3108

Dividend Payout Ratio

0%

Pasithea Therapeutics Corp ended 2024 with $38.15 million in total assets and $0 in total liabilities. Its intangible assets were valued at $38.15 million while shareholder equity stood at $35.59 million.

Pasithea Therapeutics Corp ended 2024 with $0 in deferred long-term liabilities, $2.23 million in other current liabilities, 17997.00 in common stock, $-26657789.00 in retained earnings and $1.26 million in goodwill. Its cash balance stood at $26.65 million and cash and short-term investments were $26.65 million. The company’s total short-term debt was $303,011 while long-term debt stood at $0.

Pasithea Therapeutics Corp’s total current assets stands at $28.04 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $122500.00 compared to accounts payable of $0 and inventory worth $814573.00.

In 2024, Pasithea Therapeutics Corp's operating cash flow was $0 while its capital expenditure stood at $3108.

Comparatively, Pasithea Therapeutics Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.54

52-Week High

$1.33

52-Week Low

$0.31

Analyst Target Price

$2

Pasithea Therapeutics Corp stock is currently trading at $0.54 per share. It touched a 52-week high of $1.33 and a 52-week low of $1.33. Analysts tracking the stock have a 12-month average target price of $2.

Its 50-day moving average was $0.57 and 200-day moving average was $0.55 The short ratio stood at 0.44 indicating a short percent outstanding of 0%.

Around 2649.5% of the company’s stock are held by insiders while 262.2% are held by institutions.